Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the stock.

Several other brokerages have also recently issued reports on EKSO. Lake Street Capital reduced their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright reduced their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Stock Up 7.9 %

NASDAQ:EKSO opened at $0.83 on Monday. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. Ekso Bionics has a twelve month low of $0.50 and a twelve month high of $3.03. The company has a market cap of $18.26 million, a PE ratio of -1.28 and a beta of 1.47. The company’s 50 day moving average is $0.71 and its two-hundred day moving average is $0.97.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same period last year, the firm earned ($0.24) earnings per share. Analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.